# Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Source: https://onco.cc/trials/nct06128551/  
OnCo record `nct06128551` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Elironrasib, Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06128551 by Revolution Medicines, Inc., with 534 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-12. Interventions recorded: Elironrasib, Daraxonrasib. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06128551
- Phase: 1/2
- Setting: Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 534

## Sources

- ClinicalTrials.gov NCT06128551: https://clinicaltrials.gov/study/NCT06128551

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Elironrasib](https://onco.cc/drugs/elironrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06128551.json